Effectiveness and frequency of dosing are the most important factors affecting acceptability of injectable HIV therapy, says US study
Vigilance over HIV drug interactions still needed
Second case of unintended HIV transmission during HIV cure study prompts questions about PrEP provision
One-third of people living with HIV in rural Tanzania report clinically relevant drug-drug interactions
How do we deal with apparent cases of PrEP failure?
96-week results of DISCOVER PrEP trial presented at European AIDS Conference
Options for two-drug simplification expand
Tenofovir (TDF) does not increase risk of kidney disease in people at low risk
Dolutegravir and raltegravir cause changes to fat cells
